ArticleCurrent oncology (Toronto, Ont.)2023
Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients.
Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.BMC cancer · 2023Pooled it
- Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Trial
- Choosing Wisely in Rural America: Surgical Management of the Axilla in Elderly Patients with Clinically Node-negative, Hormone Receptor-positive Invasive Breast Cancer.Annals of surgical oncology · 2026Article
- Mapping the landscape of Chinese patent medicines in breast cancer: a multi-database bibliometric analysis (1991-2025).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Association Between ER/PR-Positive Breast Tumors and Digestive Cancers.Diagnostics (Basel, Switzerland) · 2026Article
- Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort.Research square · 2026Article
- Patient-reported distress and correlates while on adjuvant endocrine therapy following breast cancer treatment among post-menopausal women: a group-based trajectory model analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Psychophysiological changes during breast cancer treatment: a longitudinal analysis of subjective and objective indicators.BMC women's health · 2026Article
- The Application of eHealth in Symptom Management of Patients With Breast Cancer During Endocrine Therapy: Scoping Literature Review.JMIR cancer · 2026Article
- Impact of Side Effects on 5-Year Adherence to Adjuvant Endocrine Therapy in Women with Breast Cancer: An Integrative Review.International journal of women's health · 2026Review
- Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study.Breast cancer research and treatment · 2025Article
- The effect of symptom distress on medication adherence in patients with breast cancer undergoing endocrine therapy: A moderated mediation model.Asia-Pacific journal of oncology nursing · 2025Article
- The influence of medication burden on the quality of life among patients with breast cancer undergoing adjuvant endocrine therapy: The mediating role of medication beliefs.Asia-Pacific journal of oncology nursing · 2025Article
- Adherence to oral anticancer medications in metastatic versus nonmetastatic breast cancer patients: Insights from a low-middle-income country.Exploratory research in clinical and social pharmacy · 2025Article
- Adherence and Compliance with Endocrine Treatment After Primary Breast Cancer Treatment: A Cross-Sectional Qualitative Study.Medicina (Kaunas, Lithuania) · 2025Article
- Impact of motivational interviewing on psychosocial and symptom outcomes during breast cancer endocrine therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Persistence to Adjuvant Endocrine Therapy for Breast Cancer in Botswana: An Observational Cohort Analysis.Breast care (Basel, Switzerland) · 2025Article
- The impact of COVID-19 pandemic on treatment adherence of patients with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Multilevel Factors Influencing Perceived Barriers to Adjuvant Endocrine Therapy Among Breast Cancer Patients at Medication Onset.International journal of environmental research and public health · 2025Article
- Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment.
methodsA total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre.
resultsSide effects were reported by 81% of patients, 84% of those taking tamoxifen and 80% of those taking aromatase inhibitors (AIs). The most common side effect in the tamoxifen group was hot flashes (55.6%), while in the AI group it was arthralgia (60.6%). The addition of GnRH agonists to both tamoxifen and AI significantly worsened all menopausal symptoms. Overall, 12% of patients definitively discontinued AET due to side effects, 6.4% during the first 5 years and 24% during extended therapy. Patients who had previously received chemotherapy or radiotherapy reported a significantly lower discontinuation rate.
conclusionsAET side effects represent a significant problem in breast cancer survivors leading to irregular assumption and discontinuation of therapy. Adherence to AET may be improved by trustful patient-physician communication and a good-quality care network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.